<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831541</url>
  </required_header>
  <id_info>
    <org_study_id>FirstAHFujian6</org_study_id>
    <nct_id>NCT04831541</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer</brief_title>
  <official_title>68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the potential usefulness of 68Ga-PSMA-11 positron emission tomography/computed&#xD;
      tomography (PET/CT) for the diagnosis of primary and metastatic lesions, efficacy assessment&#xD;
      and recurrence monitoring in various types of cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with various types of cancer underwent 68Ga-PSMA-11 PET/CT either for an initial&#xD;
      assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard&#xD;
      uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV),&#xD;
      negative predictive value (NPV) and accuracy of 68Ga-PSMA-11 PET/CT were calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value (SUV)</measure>
    <time_frame>30 days</time_frame>
    <description>Standardized uptake value (SUV) of 68Ga-PSMA-11 for each target lesion of subject or suspected primary tumor or/and metastasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic efficacy</measure>
    <time_frame>30 days</time_frame>
    <description>The sensitivity, specificity and accuracy of 68Ga-PSMA-11 PET/CT were calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Positron-Emission Tomography</condition>
  <arm_group>
    <arm_group_label>68Ga-PSMA-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA-11</intervention_name>
    <description>Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.</description>
    <arm_group_label>68Ga-PSMA-11</arm_group_label>
    <other_name>Diagnostic Test: PET/CT scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (i) adult population (aged 18 years or order); (ii) patients with suspected or new&#xD;
        diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT,&#xD;
        tumor markers and pathology report); (iii) patients who had scheduled 68Ga-PSMA-11 PET/CT&#xD;
        scan; (iv) patients who were able to provide informed consent (signed by participant,&#xD;
        parent or legal representative) and assent according to the guidelines of the Clinical&#xD;
        Research Ethics Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (i) patients with pregnancy; (ii) the inability or unwillingness of the research&#xD;
        participant, parent or legal representative to provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weibing Miao, MD</last_name>
    <phone>86-0591-87981618</phone>
    <email>miaoweibing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaoming Chen, MD</last_name>
    <phone>86-0591-87981619</phone>
    <email>shaoming81@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Miao, MD</last_name>
      <phone>+86 591 87981618</phone>
      <email>miaoweibing@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaixian Lin, MD</last_name>
      <phone>+86 591 87981619</phone>
      <email>kaysonlin@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Weibing Miao, PhD</investigator_full_name>
    <investigator_title>Director, Department of Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

